Professor Laure Marignol

• Lim D, Quah DS, Leech M, Marignol L, Clinical potential of boron neutron capture therapy for locally recurrent inoperable previously irradiated head and neck cancer., Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine, 2015Journal Article, 2015, DOI , TARA - Full Text
• Lawlor H, Meunier A, McDermott N, Lynch TH, Marignol L, Identification of suitable endogenous controls for gene and miRNA expression studies in irradiated prostate cancer cells., Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 36, (8), 2015, p6019-28Journal Article, 2015, DOI
• Dullea A, Marignol L, MGMT testing allows for personalised therapy in the temozolomide era., Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2015Review Article, 2015, DOI
• Moran DC, Marignol L, Fagan AJ, Dunne R, Perry AS, O'Driscoll D, Gaffney E, Lynch TH, Meaney JFM, Hollywood DH, Threshold-based parametric analysis of diffusion-weighted magnetic resonance imaging at 3.0 Tesla to identify men with prostate cancer, Adv Mod Oncol Res , 1, (2), 2015, p141 - 150Journal Article, 2015
• Marignol, L., Targeting notch in prostate cancer - Combination is the key, 11, (7), 2014Review Article, 2014
• McLaughlin, J., Marignol, L., Radiotherapy scheduling using prime numbers, Journal of Radiotherapy in Practice , 13, (3), 2014, p317-321Journal Article, 2014, DOI
• Martin, L.M., Marples, B., Lynch, T.H., Hollywood, D., Marignol, L., Erratum to Exposure to low dose ionizing radiation: Molecular and clinical consequences [Cancer Lett. 338 (2) (2013) 209-218], 349, (1), 2014Review Article, 2014
• Davies, A.M., Vajda, A., Ryan, S.L., Marignol, L., New approaches to cell based assays for high content screening and analysis, 18, (3), 2013, p23-28Review Article, 2013
• Devine A, Marignol L, Potential of Amifostine for Chemoradiotherapy and Radiotherapy-associated Toxicity Reduction in Advanced NSCLC: A Meta-Analysis., Anticancer research, 36, (1), 2016, p5-12Journal Article, 2016
• McDermott N., Meunier A., Mooney B., Nortey G., Hernandez C., Hurley S., Hurley S., Lynam-Lennon N., Barsoom S., Bowman K., Marples B., Jones G., Marignol L., Fractionated radiation exposure amplifies the radioresistant nature of prostate cancer cells, Scientific Reports, 6, 2016Journal Article, 2016, DOI
• Meunier A., Flores A., McDermott N., Rivera-Figueroa K., Perry A., Lynch T., Redalen K., Marignol L., Hypoxia regulates Notch-3 mRNA and receptor activation in prostate cancer cells, Heliyon, 2, (5), 2016Journal Article, 2016, DOI
• Lynam-Lennon N., Bibby B., Mongan A., Marignol L., Paxton C., Geiersbach K., Geiersbach K., Bronner M., Bronner M., O"Sullivan J., Reynolds J., Maher S., Maher S., Low MiR-187 expression promotes resistance to chemoradiation therapy in vitro and correlates with treatment failure in patients with esophageal adenocarcinoma, Molecular Medicine, 22, 2016, p388-397Journal Article, 2016, DOI
• Sarah Caufield, Laure Marignol, Gerard Menezes, Claire Poole, Nomograms are key decision making tools in prostate cancer radiation therapy, Urologic Oncology: Seminars and Original Investigations, 36, (6), 2018, p283 - 292Review Article, 2018
• Inder, S., O'Rourke, S., McDermott, N., (...), Lynch, T., Marignol, L. , The Notch-3 receptor: A molecular switch to tumorigenesis?, Cancer treatment reviews, 60, 2017, p69-76Review Article, 2017, DOI
• Hutchinson, J., Marignol, L. , Clinical Potential of Statins in Prostate Cancer Radiation Therapy., Anticancer research, 37, (10), 2017, p5363-5372Review Article, 2017, DOI
• Haruna, F., Lipsett, A., Marignol, L. , Topical Management of Acute Radiation Dermatitis in Breast Cancer Patients: A Systematic Review and Meta-Analysis., Anticancer research, 37, (10), 2017, p5343-5353Journal Article, 2017, DOI
• Fitzpatrick C, Lynch O, Marignol L., 68Ga-PSMA-PET/CT Has a Role in Detecting Prostate Cancer Lesions in Patients with Recurrent Disease., Anticancer research, 37, (6), 2017, p2753-2760Review Article, 2017, DOI
• Marignol, L., Notch signalling: The true driver of small cell lung cancer?, Translational Cancer Research, 6, 2017, pS1191-S1196Review Article, 2017, DOI , URL
• O'Brien, R. and Marignol, L., The Notch-1 receptor in prostate tumorigenesis, Cancer Treatment Reviews, 56, 2017, p36-46Review Article, 2017, DOI , URL
• Samsuri, N.A.B. and Leech, M. and Marignol, L., Metformin and improved treatment outcomes in radiation therapy â€" A review, Cancer Treatment Reviews, 55, 2017, p150-162Review Article, 2017, DOI , URL
• Perry, A.S. and O'Hurley, G. and Raheem, O.A. and Brennan, K. and Wong, S. and O'Grady, A. and Kennedy, A.M. and Marignol, L. and Murphy, T.M. and Sullivan, L. and Barrett, C. and Loftus, B. and Thornhill, J. and Hewitt, S.M. and Lawler, M. and Kay, E. and Lynch, T. and Hollywood, D., Erratum: Gene expression and epigenetic discovery screen reveal methylation of SFRP2 in prostate cancer (International Journal of Cancer (2013) 132:8 (1771-80) DOI: 10.1002/ijc.27798)), International Journal of Cancer, 132, (11), 2013Journal Article, 2013, DOI , URL
• Glynn A, Marignol L, Forde E, Focal therapy: A treatment option for localized prostate cancer? , Advances in Modern Oncology Research, 2018Review Article, 2018, DOI
• Scientific Report, Nature, [eds.], 2014Editorial Board, 2014
• Inder, S. and Bates, M. and McDermott, N. and Domad, J. and Schneider, J. and Erdmann, G. and Finn, S. and Manecksha, R. P. and Lynch, T. H. and Marignol, L., Identification of a protein signature of radioresistance in a prostate cancer model, The British Association for Urological Surgeons, 120, 2017, pp24-24Poster, 2017, URL
• Azmi, Aini and Dillon, Ruth and Marignol, Laure and Borghesi, Simona and Dunne, Mary and Power, Richard and O'Neill, Brian, Active surveillance for low-risk prostate cancer: Practice across Europe, Journal of Clinical Oncology, 30, (5), 2012Poster, 2012, URL
• Bolton, E. and Moran, D. and Meunieur, A. and Marignol, L. and Hollywood, D. and Lynch, T. H. and Perry, A., Real Time Expression Analysis of a Microrna Signature of Prostate Cancer in Prostate Cell Lines and Tissue Specimens, 181, 2012, ppS169-S170Poster, 2012, URL
• Bolton, E. M. and Moran, D. and Meunier, A. and Vajda, A. and O'Kelly, F. and Thurman, J. and O'Connor, R. and Marignol, L. and Hollywood, D. and Lynch, T. H. and Perry, A. S., Epigenetic profiling in urine for the detection of aggressive prostate cancer, 100, 2013, pp63-63Poster, 2013, URL
• Bolton, E. M. and Moran, D. C. and Meunier, A. and O'Kelly, F. and Marignol, L. and Hollywood, D. and Lynch, T. H. and Perry, A. S., Real time expression analysis of a microRNA signature of prostate cancer in prostate cell lines and tissue specimens, 100, 2013, pp63-63Poster, 2013, URL
• D'Arcy, F. and Foley, R. and Perry, A. and Marignol, L. and Gaffney, E. and Dunne, B. and Lawler, M. P. and Watson, R. W. G. and Fitzpatrick, J. M. and Lynch, T. H., RNASEL and its role in Irish prostate cancer patients, 100, 2007, pp12-13Poster, 2007, URL
• D'Arcy, F. and Foley, R. and Perry, A. and Marignol, L. and Lawler, M. and Gaffney, E. and Watson, R. G. W. and Fitzpatrick, J. M. and Lynch, T. H., No evidence of XMRV in irish prostate cancer patients with the R462q mutation, 7, (3), 2008, pp271-271Poster, 2008, DOI , URL
• Foley, R. and Marignol, L. and Lawler, M., Prodrug activation therapy kills prostate cancer cells in a three-dimensional culture model, 100, 2007, pp24-24Poster, 2007, URL
• Forde, J. C. and Blake, O. and Casey, R. G. and Marignol, L. and McDermott, T. E. and Grainger, R. and Crowley, V. E. and Lynch, T. H., THE INTER-HOSPITAL VARIABILITY OF 6 DIFFERENT PSA ASSAY KITS CURRENTLY IN USE THROUGHOUT IRELAND, Irish Journal of Medical Science, IACR, 179, 2010, ppS372-S372Poster, 2010, URL
• Forde, J. C. and Hollywood, D. and Lawler, M. and Lynch, T. H. and Marignol, L. and Marignol, L., Investigation of the cytotoxic properties of a novel microtubule-targeting compound, PBOX-15, in hypoxic prostate cancer cell lines, Bju International, 106, (1), 2010, pp52-53Poster, 2010, URL
• Forde, J. C. and Maginn, E. and McElligott, A. M. and Martin, L. M. and Williams, D. C. and Zisterer, D. and Lawler, M. and Hollywood, D. and Lynch, T. H. and Marignol, L., AN IN VITRO INVESTIGATION OF THE CYTOTOXIC AND RADIO-SENSITISING PROPERTIES OF A NOVEL MICROTUBULE TARGETING AGENT, PBOX-15, IN HYPOXIC PROSTATE CANCER CELL LINES, European Urology Supplements, EAU, 10, (2), 2011, pp292-292Poster, 2011, URL
• Forde, J. C. and Maginn, E. and McElligott, A. M. and Martin, L. M. and Williams, D. C. W. and Zisterer, D. and Hollywood, D. and Lawler, M. and Lynch, T. H. and Marignol, L., RADIOSENSITIZATION OF HYPOXIC PROSTATE CANCER CELL LINES USING A NOVEL MICROTUBULE TARGETING AGENT: PBOX-15, Irish Journal of Medical Science, IACR, 179, 2010, ppS372-S372Poster, 2010, URL
• Forde, J. C. and Perry, A. and Hollywood, D. and Lawler, M. and Lynch, T. H. and Marignol, L., Downregulation of HIF-1 A and lowered TUBB3 expression levels leads to preferential sensitivity of hypoxic prostate cancer cells tol docetaxel, 98, (6), 2011, ppE8-E8Poster, 2011, URL
• Hennessey, D. and Coffey, M. and Lynch, T. and Lawler, M. and Hollywood, D. and Marignol, L., Adaptation to low oxygenation levels modify the radioresponse of prostate cancer cells in vitro, 98, (6), 2011, ppE8-E8Poster, 2011, URL
• Hennessey, D. and Martin, L. and Hollywood, D. and Lynch, T. H. and Marignol, L., EXPOSURE TO REDUCED OXYGENATION FOLLOWING RADIATION EXPOSURE ENHANCES THE SURVIVAL OF PROSTATE CANCER CELLS IN VITRO: IMPLICATIONS FOR RADIATION THERAPY DELIVERY, Irish Medical Science Journal , IACR, 179, 2010, ppS351-S351Published Abstract, 2010, URL
• Keane, J. P. and Foley, R. and Marignol, L. and Hollywood, D. and Lynch, T. H., THE EFFECT OF CALPAIN ACTIVATION IN THE 22Rv1 PROSTATE CANCER CELL LINE, 179, 2010, ppS350-S350Published Abstract, 2010, URL
• Lennon, N. Lynam and Reynolds, J. V. and Marignol, Laura and Sheils, O. M. and Pidgeon, G. P. and Maher, S. G., MiR-31 modulates tumour sensitivity to radiation in oesophageal cancer, 180, 2011, ppS276-S276Poster, 2011, URL
• Marignol, L. and Foley, R. and Southgate, T. D. and Coffey, M. and Hollywood, D. and Lawler, M., Hypoxia-inducible suicide gene therapy approach radiosensitises prostate cancer cells, 100, 2007, pp32-32Published Abstract, 2007, URL
• Martin, L. and Marignol, L., Sequence effect on the survival of prostate cancer cells may potentiate daily radiation therapy delivery, 84, 2007, ppS281-S281Poster, 2007, URL
• McDermott, N. and Meunier, A. and Hernandez, C. and Bowman, K. J. and Jones, G. D. and Marignol, L., Identification of a miRNAs signature of radioresistance in a prostate cancer model, 75, 2015Poster, 2015, DOI , URL
• Mongan, A. M. and Lynam-Lennon, N. and Marignol, L. and Maher, S. and O'Farrell, N. J. and Pidgeon, G. and O'Sullivan, J. and Reynolds, J. V., Obesity fuels genomic instability and radioresistance in oesophageal cancer, 182, 2013, ppS38-S38Poster, 2013, URL
• Mongan, A. M. and Lynam-Lennon, N. and Marignol, L. and Maher, S. and Pidgeon, G. and O'Sullivan, J. N. and Reynolds, J. V., Obesity and radiosensitivity status influence genomic instability events: Anaphase bridge formation and spindle assembly checkpoint gene expression in oesophageal cancer, 100, 2013, pp48-48Poster, 2013, URL
• Mongan, A. M. and Reynolds, J. and Lynam-Lennon, N. and Marignol, L. and Maher, S. and Pidgeon, G. and O'Sullivan, J., Levels of obesity influences a nuclear instability event: Anaphase bridge formation in oesophageal cancer, 180, 2011, ppS262-S262Poster, 2011, URL
• Mongan, A. M. and Reynolds, J. and Lynam-Lennon, N. and Marignol, L. and Maher, S. and Pidgeon, G. and O'Sullivan, J., Obesity Status Influence Nuclear Instability Events: Anaphase Bridge Formation and Spindle Assembly Checkpoint Gene Expression in Oesophageal Cancer, 181, 2012, ppS152-S153Poster, 2012, URL
• Moran, D. and Marignol, L. and Fagan, A. and Hollywood, D. and Meaney, J. and Lynch, T., Functional endorectal MRI at 3 Tesla for the detection and staging of prostate cancer: Correlation with prostatectomy specimens, 180, 2011, ppS269-S270Poster, 2011, URL
• O'Kelly, F. and Perry, A. S. and Meunier, A. and Wong, S. and Hollywood, D. and Marignol, L. and Lynch, T. H., Over-expression of a novel microRNA, miR-24, affects prostate cancer cell growth and proliferation, and contributes to radio-senstivity of prostate cancer cells in vitro, 11, (1), 2012, ppE849-U790Poster, 2012, URL
• Raheem, O. A. and Powell, A. and Kennedy, A. M. and Murphy, T. and Foley, R. and Marignol, L., Investigation into methylation of the Secreted Frizzled Related Proteins (SFRP) family of Wnt antagonists in prostate cancer, 103, 2009, pp19-20Poster, 2009, URL
• Thomas, A. Z. and Foley, R. and Marignol, L. and Hollywood, D. and Lynch, T. and Lawlor, M., The effect of the HIF-1 alpha C1772T heterozygous genotype on prostate cancer risk and HIF-1 alpha expression in prostate tissue, 97, 2010, pp3-4Poster, 2010, URL
• Thomas, A. Z. and Marignol, L. and Foley, R. and Perry, A. and Tewari, P. and O'Grady, T. and Kay, E. and Dunne, B. and Loftus, B. and Hollywood, D. and Lynch, T. and Lawler, M., Enhanced expression of hypoxia markers in cell lines and in clinical specimens of malignant prostate tissue: A factor in disease progression?, 100, 2007, pp40-41Poster, 2007, URL
• Thomas, A. Z. and Marignol, L. and Foley, R. and Perry, A. and Tewari, P. and O'Grady, T. and Kay, E. and Dunne, B. and Loftus, B. and Hollywood, D. and Lynch, T. and Lawler, M., Enhanced expression of hypoxia markers in cell lines and in clinical specimens of malignant prostate tissue: A factor in disease progression?, 100, 2007, pp40-41Poster, 2007, URL
• Traynor, S. and Gilham, C. and Foley, R. and Fairbairn, L. J. and Southgate, T. D. and Worthington, J. and Coffey, M. and Hollywood, D. and Lawler, M. and Marignol, L., Utilising a hypoxia-inducible suicide gene therapy strategy in combination with radiation to target prostate cancer cells, 81, 2006, ppS477-S477Poster, 2006, URL
• Vajda, Alice and Marignol, Laure and Foley, Ruth and Hollywood, Donal and Lawler, Mark, Hypoxia, androgen and radiation-inducible suicide gene therapy for the treatment of prostate cancer, 20, (11), 2009, pp1519-1519Poster, 2009, URL
• Wall, V. and Marignol, L. and Elbeltagi, M. N., Radiotherapy in Paediatrics: A Survey of International Patterns of Practice of Image Guided Radiation Therapy and Planning Target Volume, 63, 2016, ppS64-S64Oral Presentation, 2016, URL
• Marignol L., Predicting Treatment Outcomes: The Case for Hypoxia Gene Signatures., EBioMedicine, 2018Review Article, 2018, DOI
• Sarah Barrett, Gerard G. Hanna, Laure Marignol, An overview on personalisation of radiotherapy prescriptions in locally advanced non-small cell lung cancer: Are we there yet?, Radiotherapy and Oncology, 128, (3), 2018, p520 - 533Review Article, 2018, DOI
• Barrett S, Thirion P, Harper D, Simpkin A, Leech M, Hickey K, Ryan L, Marignol L, Dosimetric impact of uncorrected systematic yaw rotation in VMAT for peripheral lung SABR, . Reports of Practical Oncology & Radiotherapy, 24, (6), 2019, p520 - 527Journal Article, 2019, URL
• S Inder, M Bates, N Ni Labhrai, N McDermott, J Schneider, G Erdmann, T Jamerson, AN Flores, A Prina-Mello, P Thirion, PR Manecksha, D Cormican, S Finn, T Lynch, L Marignol, Multiplex profiling identifies clinically relevant signalling proteins in an isogenic prostate cancer model of radioresistance, Scientific Reports, 9, 2019, p1 - 12Journal Article, 2019, DOI , TARA - Full Text
• Sarah Barrett, Michelle Leech, Dr Laure Marignol, Time trend analysis of target volume auto-contouring in locally advanced NSCLC over the course of RT, ESTRO 2020, Vienna, Austria, 2020Poster, 2020, DOI
• Darragh Waters , Adrian Fuentes-Bonachera , Armelle Meunier , Rustom P. Manecksha, Laure Marignol and Thomas H. Lynch, Kidney Cancer Research: Sex-Inclusive but Sex-Unspecific, Clinical Oncology and Research, 2020Journal Article, 2020, URL
• Wall V, Marignol L, ElBeltagi N., Image-Guided Radiotherapy in Paediatrics: A Survey of International Patterns of Practice., Journal of medical imaging and radiation sciences, 49, (3), 2018, p265-269Journal Article, 2018, DOI
• Elbeltagi M.N., Wall V., Marignol L., Planning target volume (PTV) margin practice patterns in adults and paediatrics among the Paediatric Radiation Oncology Society (PROS) members: An international survey, Journal of Radiotherapy in Practice, 17, (4), 2018, p373 - 376Journal Article, 2018, DOI
• Griffin F., Marignol L., Therapeutic potential of melatonin for breast cancer radiation therapy patients, International Journal of Radiation Biology, 94, (5), 2018, p472 - 477Review Article, 2018, DOI
• McDermott N., Meunier A., Wong S., Buchete V., Marignol L., Profiling of a panel of radioresistant prostate cancer cells identifies deregulation of key miRNAs, Clinical and Translational Radiation Oncology, 2, 2017, p63 - 68Journal Article, 2017, DOI
• Michelle Leech, John Gaffney, Laure Marignol, Improving non-invasive detection of prostate cancer using diffusion-weighted MRI, Advances in Modern Oncology Research , 2, (6), 2016Review Article, 2016
• Laure Marignol, Radiobiology of particles therapy: principles and latest advances, ESTRO meets Asia , Singapore, 2019, European Society for Radiotherapy and OncologyInvited Talk, 2019, URL
• Laure Marignol, Molecular radiation response of breast cancer: advances and clinical potential, ESTRO meets Asia , Singapore, 6-8th December, 2019, European Society for Radiotherapy and OncologyInvited Talk, 2019, URL
• McDermott N,Inder S, Schneider J, Erdmann G, Meunier A., Lynch T, Marignol L, Identifying a novel molecular switch of the radiation response of prostate cancer cells, Radiation Research Society Annual Meeting, Cancun, Mexico, October 15-18, 2017Oral Presentation, 2017, URL
• Laure Marignol, Gene editing: How this technique can be used to study radiation responses?, 2017, S1 - S1ppInvited Talk, 2017, DOI
• Inder, S, Bates, M, McDermott, N, Saluzzo, J, Ni Labhrai, N , Schneider, J, Erdmann, G, Lynch, , Marignol, L, Lessons from isogenic models of radioresistant prostate cancer cells, 37th Meeting of the European-Society-for-Radiotherapy-and-Oncology (ESTRO), Barcelona, SPAIN, 2018Oral Presentation, 2018, DOI
• McDermott, N.; Meunier, A.; Haynes, C.; Flores, A.; O'Callaghan, A.; Marignol, L., Therapeutic potential of the YB-1/Notch-3 interaction in prostate cancer, 35th Scientific Meeting of the European Society for Radiotherapy and Oncology (ESTRO), Turin, Italy, 2016Poster, 2016, DOI
• McDermott N, Inder S, Schneider J, Erdmann G,Meunier A., Lynch T, Marignol L, Radioresistance profiling identifies Notch-3 signalling as a molecular switch to molecular radiation response of prostate cancer cells , 15th International Wolfsberg Meeting, Switzerland, 2017Poster, 2017
• James Clerkin, Kate Connor, Kieron Sweeney, Kieron White, Stephen G. Maher, Laure Marignol, Jochen Prehn , David O'Brien, Annette T. Byrne, Establishing a clinically relevant model of Glioblastoma in young and aged mice, encompassing standard of care treatment and immune checkpoint inhibition (ICI, Irish Association for Cancer Research , Galway, February 2020, 2020Poster, 2020
• Barrett S , Simpkin AJ , Walls G , Leech M , Marigno Ll , Geometric and dosimetric evaluation of a commercially available auto-segmentation tool for gross tumour volume delineation in locally advanced Non-Small Cell Lung Cancer: a feasibility study, Journal of Clinical Oncology, 2020Journal Article, 2020, DOI
• Wei Ang, Laure Marignol, Pro-con of proton: dosimetric advantages of intensity-modulation over passive scatter for thoracic malignancies , Technical Innovations & Patient Support in Radiation Oncology, 2020Review Article, 2020
• Bates, Mark, Boland, Anna, McDermott, Niamh, Marignol, Laure, YB-1: The key to personalised prostate cancer management?, Cancer Letters, 2020Journal Article, 2020, DOI
• Elizabeth Forde, Michelle Leech, Charlotte Robert, Elizabeth Heron, Laure Marignol, Influence of Inter-Observer Delineation Variability on Radiomic Features of the Parotid Gland, Radiotherapy and Oncology, ESTRO2020, Online, August 2020, 2020Poster, 2020
• Forde E, Leech M, Robert C, Heron E, Marignol L, Influence of Inter-Observer Delineation Variability on Radiomic Features of the Parotid Gland, Physica Medica, (82), 2021, p240 - 248Journal Article, 2021, DOI
• Adrian Fuentes-Bonachera, Darragh Waters, A. Meunier, Rustom P. Manecksha, Laure Marignol, Thomas H. Lynch, Sex in Bladder cancer research: an overview, SN Comprehensive Clinical Medicine, 2021Journal Article, 2021
• Armelle Meunier, Laure Marignol, The radiotherapy cancer patient: female inclusive, but male dominated, International Journal of Radiation Biology, 2020, p1--21Journal Article, 2020
• Michelle Leech, Sarah Osman, Suneil Jain, Laure Marignol, Mini review: Personalization of the radiation therapy management of prostate cancer using MRI-based radiomics, Cancer Letters, 2020Journal Article, 2020
• Leech M, Leijenaar R, Hompland T, Gaffney J, Lyng H, Marignol L, Exploring hypoxia in prostate cancer with T2-weighted MRI radiomics and pimonidazole scoring, Radiotherapy and Oncology, ESTRO 2021, Madrid, Spain, 161, Elsevier, 2021, ppS1526 - S1527Poster, 2021, DOI
• Radio-resistant in vitro models for cancer research in, editor(s)Adriele Prina-Mello Dania Movia , Methods in Cancer Cell Culture, Springer Nature, 2022, [Laure Marignol]Book Chapter, 2022
• Mascan, B. and Marignol, L., Aspirin in the management of patients with prostate cancer undergoing radiotherapy: Friend or Foe?, Anticancer Research, 38, (4), 2018, p1897-1902Journal Article, 2018, DOI , URL
• Clerkin, James and Connor, Kate and Sweeney, Kieron and White, Kieron and Shiels, Liam and Maher, Stephen and Marignol, Laure and Prehn, Jochen H. M. and O'Brien, David and Byrne, Annette, ESTABLISHING A CLINICALLY RELEVANT MODEL OF MESENCHYMAL GLIOBLASTOMA (GBM) TO STUDY RESPONSE TO STANDARD OF CARE TREATMENT AND IMMUNE CHECKPOINT INHIBITION (ICI)., 25th Virtual Annual Scientific Meeting and Education Day of the Society-for-Neuro-Oncology (SNO), ELECTR NETWORK, NOV 19-21, 2020, 22, (2), 2020, pp230Poster, 2020
• Inder, S. and Bates, M. and McDermott, N. and Domad, J. and Schneider, J. and Erdmann, G. and Finn, S. and Manecksha, R. P. and Lynch, T. H. and Marignol, L., Profiling of radioresistant prostate cancer cells identifies deregulation of key protein, BJU INTERNATIONAL, 120, (2, SI), 2017, p24Journal Article, 2017
• McDermott, N. and Meunier, A. and Jameson, T. and Mansour, A. and Haynes, C. and Flores, A. and O'Callaghan, A. and Marignol, L., Novel molecular radiobiology for personalised prostate cancer radiotherapy, RADIOTHERAPY AND ONCOLOGY, 123, (1), 2017, pS200Journal Article, 2017, DOI
• Devine, A. and Marignol, L., Meta-analysis: can amifostine reduce chemoradiotherapy and radiotherapy toxicity in advanced NSCLC?, RADIOTHERAPY AND ONCOLOGY, 119, (1), 2016, pS964Journal Article, 2016, DOI
• Floyd, R. and McDermott, N. and Meunier, A. and Marignol, L., Radiosensitisation properties of PI3K/AKT inhibitor GDC-0941 in prostate cancer cells, RADIOTHERAPY AND ONCOLOGY, 115, (1), 2015, pS572Journal Article, 2015
• McDermott, N. and Meunier, A. and Hernandez, C. and Bowman, K. J. and Jones, G. D. and Marignol, L., Identification of MiRNAs associated with radioresistance in a prostate cancer model, RADIOTHERAPY AND ONCOLOGY, 115, (1), 2015, pS670Journal Article, 2015
• Roe, K. and Mikalsen, L. T. G. and van der Kogel, A. J. and Bussink, J. and Lyng, H. and Ree, A. H. and Marignol, L. and Olsen, D. R., DCEMRI IN ASSESSMENT OF TUMOR NEOVASCULARIZATION AFTER ANDROGEN-DEPRIVATION IN EXPERIMENTAL PROSTATE CANCER: CORRELATION TO QUANTITATIVE IMMUNOHISTOCHEMISTRY, RADIOTHERAPY AND ONCOLOGY, 102, (1), 2012, pS68Journal Article, 2012
• Lynam-Lennon, Niamh and Reynolds, John V. and Marignol, Laure and Sheils, Orla M. and Pidgeon, Graham P. and Maher, Stephen G., miR-31 modulates tumor sensitivity to radiation in esophageal cancer by regulation of DNA repair genes, CANCER RESEARCH, 71, (8), 2011Journal Article, 2011, DOI
• Forde, James and Blake, Ophelia and Marignol, Laure and McDermott, T. E. D. and Grainger, Ronald and Crowley, Vivion and Lynch, Thomas, DEMONSTRATION OF THE VARIABILITY OF THE DIFFERENT TOTAL PSA ASSAYS CURRENTLY IN USE THROUGHOUT IRISH HOSPITALS, JOURNAL OF UROLOGY, 185, (4, S), 2011, pE817Journal Article, 2011, DOI
• Kelada, O. J. and Marignol, L., DOES THE USE OF ERYTHROPOIETIN-STIMULATING AGENTS IN BREAST CANCER PATIENTS WITH CHEMOTHERAPY-INDUCED ANAEMIA IMPACT ON CLINICAL OUTCOMES ? A CRITICAL REVIEW OF THE LITERATURE, RADIOTHERAPY AND ONCOLOGY, 96, (1), 2010, pS578Journal Article, 2010
• Marignol, L., 5-STEP GUIDE TO THE MANAGEMENT OF A RESEARCH PROJECT, RADIOTHERAPY AND ONCOLOGY, 96, (1), 2010, pS164Journal Article, 2010
• Marignol, L. and Martin, L. and Coffey, M. and Lawler, M. and Lynch, T. and Hollywood, D., REDUCED OXYGENATION DOES NOT PROTECT ALL PRO STATE CANCER CELLS FROM RADIATION: A NEW ROLE FOR HYPOXIA IN RADIATION THERAPY?, RADIOTHERAPY AND ONCOLOGY, 96, (1), 2010, pS596Journal Article, 2010
• Perry, Antoinette S. and O'Hurley, Gillian and Raheem, Omer A. and O'Grady, Anthony and Kennedy, Anne -Marie and Barrett, Ciara and Marignol, Laure and Murphy, Therese M. and Sullivan, Linda and Loftus, Barbara and Hewitt, Stephen M. and Kay, Elaine and Lawler, Mark, Epigenetic discovery screen identifies SFRP2 as a novel biomarker of high grade prostate cancer, CANCER RESEARCH, 70, (8), 2010Journal Article, 2010, DOI
• Raheem, O. A. and Perry, A. S. and Kennedy, A. M. and Murphy, T. M. and Foley, R. and Marignol, L. and Suillvan, L. and Loftus, B. and Lawler, M. and Lynch, T. H., INVESTIGATING PROMOTER METHYLATION OF WNT SIGNALLING ANTAGONISTS IN PROSTATE CANCER, EUROPEAN UROLOGY SUPPLEMENTS, 9, (2), 2010, p310Journal Article, 2010, DOI
• Leech, M. and Leijenaar, R.T.H. and Hompland, T. and Gaffney, J. and Lyng, H. and Marignol, L., Exploring Hypoxia in Prostate Cancer With T2-weighted Magnetic Resonance Imaging Radiomics and Pimonidazole Scoring, Anticancer Research, 43, (1), 2023, p351-357Journal Article, 2023, DOI , URL
• Forde E, Robert C, Leech M, Marignol L. , Spatial Resampling Combined with Intensity Discretization Improves Reproducibility of Radiomic Features of the Parotid Gland. (e-poster #604, European Congress of Medical Physics, Dublin, Ireland, August 2022Conference Paper
• SK Zazzera , C Poole & L Marignol, Investigating the Needs and Concerns of Lesbian, Gay, Bisexual, Transgender, Queer, or Questioning Cancer Patients, Journal of Homosexuality, 2024Journal Article, 2024
• Harris E, Marignol L., Prehabilitation for Patients with Cancer Undergoing Radiation Therapy: a Scoping Review., Clinical oncology (Royal College of Radiologists (Great Britain)), 36, (4), 2024, p254-264Journal Article, 2024
• Marignol L., Generation of Radioresistant Prostate Cancer Cells., Methods in molecular biology (Clifton, N.J.), 2645, 2023, p129-138Journal Article, 2023
• Liu T, Dahle MA, Lystad MH, Marignol L, Karlsen M, Redalen KR., In vitro and in vivo characterization of [⁶⁴Cu][Cu(elesclomol)] as a novel theranostic agent for hypoxic solid tumors., European journal of nuclear medicine and molecular imaging, 50, (12), 2023, p3576-3588Journal Article, 2023
• Marignol, L., Foley, R., Southgate, T.D., Coffey, M., Hollywood, D., Lawler, M., Hypoxia response element-driven cytosine deaminase/5-fluorocytosine gene therapy system: a highly effective approach to overcome the dynamics of tumour hypoxia and enhance the radiosensitivity of prostate cancer cells in vitro., The Journal of Gene Medicine , 11, (2), 2009, p169-179Journal Article, 2009, DOI
• Marignol L, Robson T, McCarthy HO, Worthington J, Murray MM, Hollywood D, Lawler M, Hirst DG., The tissue plasminogen activator gene promoter: a novel tool for radiogenic gene therapy of the prostate?, Journal of Gene Medicine, 10, (9), 2008, p1032-1038Journal Article, 2008, DOI
• Marignol L, Coffey M, Lawler M, Hollywood D., Hypoxia in prostate cancer: a powerful shield against tumour destruction?, Cancer Treatment Reviews, 34, (4), 2008, p313-327Review Article, 2008, DOI
• Marignol L, Coffey M, Hollywood D, Lawler M., Radiation to Control Transgene Expression in Tumors., Cancer Biological Therapy, 6, (7), 2007, p1005 - 1012Review Article, 2007, URL
• Marignol L, Lawler M, Coffey M, Hollywood D., Achieving Hypoxia-Inducible Gene Expression in Tumors., Cancer Biological Therapy, 4, (4), 2005, p359-364.Review Article, 2005, URL
• Lynn Martin, Brian Marples, Mary Coffey, Mark Lawler, Donal Hollywood, Laure Marignol, Recognition of O6MeG lesions by MGMT and mismatch repair proficiency may be a prerequisite for low-dose radiation hypersensitivity., Radiation Research, 172, (4), 2009, p405 - 413Journal Article, 2009
• Forde JC, Maginn EN, McNamara G, Martin LM, Campiani G, Williams DC, Zisterer D, McElligott AM, Lawler M, Lynch TH, Hollywood D, Marignol L, Microtubule-targeting-compound PBOX-15 radiosensitizes cancer cells in vitro., Cancer biology & therapy, 11, (4), 2011, p421-8Journal Article, 2011
• Forde JC, Perry AS, Brennan K, Martin LM, Lawler MP, Lynch TH, Hollywood D, Marignol L, Docetaxel maintains its cytotoxic activity under hypoxic conditions in prostate cancer cells., Urologic oncology, 1, 2010Journal Article, 2010, DOI
• Lynam-Lennon N, Reynolds JV, Pidgeon GP, Lysaght J, Marignol L, Maher SG, Alterations in DNA repair efficiency are involved in the radioresistance of esophageal adenocarcinoma., Radiation research, 174, (6), 2010, p703 - 711Journal Article, 2010, DOI
• Martin LM, Marples B, Coffey M, Lawler M, Lynch TH, Hollywood D, Marignol L, DNA mismatch repair and the DNA damage response to ionizing radiation: making sense of apparently conflicting data., Cancer treatment reviews, 36, (7), 2010, p518-27Review Article, 2010, DOI
• Martin L, Coffey M, Lawler M, Hollywood D, Marignol L, DNA mismatch repair and the transition to hormone independence in breast and prostate cancer., Cancer letters, 291, (2), 2010, p142-9Review Article, 2010, DOI
• Foley R, Marignol L, Keane JP, Lynch TH, Hollywood D, Comment on "Androgen-hypersensitive preclinical model of prostate cancer" by Kawata et al., The Prostate, 71, (6), 2010, p559 - 560Review Article, 2010, DOI
• Foley R, Marignol L, Thomas AZ, Cullen IM, Perry AS, Tewari P, O'Grady A, Kay E, Dunne B, Loftus B, Watson WR, Fitzpatrick JM, Woodson K, Lehman T, Hollywood D, Lynch TH, Lawler M, The HIF-1alpha C1772T polymorphism may be associated with susceptibility to clinically localised prostate cancer but not with elevated expression of hypoxic biomarkers., Cancer biology & therapy, 8, (2), 2009, p118-24Journal Article, 2009, URL , TARA - Full Text
• Hennessey D, Martin LM, Atzberger A, Lynch TH, Hollywood D, Marignol L, Exposure to hypoxia following irradiation increases radioresistance in prostate cancer cells., Urologic oncology, 1, 2011Journal Article, 2011, DOI
• Vajda A, Marignol L, Foley R, Lynch TH, Lawler M, Hollywood D, Clinical potential of gene-directed enzyme prodrug therapy to improve radiation therapy in prostate cancer patients., Cancer treatment reviews, 37, (8), 2011, p643-54Review Article, 2011
• Røe K, Mikalsen LT, van der Kogel AJ, Bussink J, Lyng H, Ree AH, Marignol L, Olsen DR, Vascular responses to radiotherapy and androgendeprivation therapy in experimental prostate cancer., Radiation oncology (London, England), 7, (1), 2012, p75Journal Article, 2012
• O'Kelly F, Marignol L, Meunier A, Lynch TH, Perry AS, Hollywood D, MicroRNAs as putative mediators of treatment response in prostate cancer., Nature reviews. Urology, 2012Review Article, 2012, DOI
• James C. Forde, Laure Marignol, Ophelia Blake, Ted McDermott, Ronald Grainger, Vivien E. Crowley, Thomas H. Lynch, Standardization of assay methods reduces variability of total PSA measurements: an Irish study, 2012Poster, 2012, DOI
• Lynam-Lennon N, Reynolds JV, Marignol L, Sheils OM, Pidgeon GP, Maher SG, MicroRNA-31 modulates tumour sensitivity to radiation in oesophageal adenocarcinoma., Journal of molecular medicine (Berlin, Germany), 2012Journal Article, 2012, DOI
• Perry AS, O'Hurley G, Raheem OA, Brennan K, Wong S, O'Grady A, Kennedy AM, Marignol L, Murphy TM, Sullivan L, Barrett C, Loftus B, Thornhill J, Hewitt SM, Lawler M, Kay E, Lynch T, Hollywood D, Gene expression and epigenetic discovery screen reveal methylation of SFRP2 in prostate cancer., International journal of cancer. Journal international du cancer, 2012Journal Article, 2012
• Foley R, Marignol L, Keane JP, Lynch TH, Hollywood D., Androgen hypersensitivity in prostate cancer: molecular perspectives on androgen deprivation therapy strategies, Prostate, 71, (5), 2011Review Article, 2011, DOI
• Martin LM, Marples B, Davies AM, Atzberger A, Edwards C, Lynch TH, Hollywood D, Marignol L, DNA mismatch repair protein MSH2 dictates cellular survival in response to low dose radiation in endometrial carcinoma cells., Cancer letters, 2013Journal Article, 2013
• Vajda A, Marignol L, Barrett C, Madden SF, Lynch T, Hollywood D, Perry AS, Gene expression in prostate cancer: the importance of the endogenous control. , The Prostate, 2013Journal Article, 2013
• Martin LM, Marples B, Lynch TH, Hollywood D, Marignol L, Exposure to Low Dose Ionizing Radiation: Molecular and Clinical Consequences., Cancer letters, 2013Review Article, 2013
• Røe K, Bratland A, Vlatkovic L, Ragnum HB, Saelen MG, Olsen DR, Marignol L, Ree AH, Hypoxic Tumor Kinase Signaling Mediated by STAT5A in Development of Castration-Resistant Prostate Cancer., PloS one, 8, (5), 2013, pe63723Journal Article, 2013, DOI , TARA - Full Text
• Marignol L, Rivera-Figueroa K, Lynch T, Hollywood D, Hypoxia, notch signalling, and prostate cancer., Nature reviews. Urology, 10, (7), 2013, p405-13Review Article, 2013
• Schoenherr D, Krueger SA, Martin L, Marignol L, Wilson GD, Marples B, Determining if low dose hyper-radiosensitivity (HRS) can be exploited to provide a therapeutic advantage: A cell line study in four glioblastoma multiforme (GBM) cell lines., International journal of radiation biology, 2013Journal Article, 2013
• McDermott N, Meunier A, Lynch T, Hollywood D, Marignol L, Isogenic radiation resistant cell lines: Development and Validation strategies., International journal of radiation biology, 2013Review Article, 2013
• Flores AN, McDermott N, Meunier A, Marignol L, NUMB inhibition of NOTCH signalling as a therapeutic target in prostate cancer., Nature reviews. Urology, 11, (9), 2014, p499-507Review Article, 2014
• Azmi A, Dillon RA, Borghesi S, Dunne M, Power RE, Marignol L, O'Neill BD, Active surveillance for low-risk prostate cancer: diversity of practice across Europe., Irish journal of medical science, 2014Journal Article, 2014
• Kelada O, Marignol L, Erythropoietin-stimulating agents and clinical outcomes in metastatic breast cancer patients with chemotherapy-induced anemia: a closed debate?, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 35, (6), 2014, p5095-100Review Article, 2014

Radiobiology is a field of science that emerged from our ability to treat diseases with ionising radiation. I am intrigued by the complexity of the biological effects of radiation and feel compelled to pick at the puzzle. Cancer patients will never meet me, but I rejoice in the opportunity to help radiation Oncologists solve their challenges in ensuring that each patient can receive the best treatment for their disease. Radiobiology's pillars were defined by a few great and I feel privileged to have brought this field to Trinity and to both disseminate its legacy and contribute to its future in Ireland and internationally. I have extensively studied the impact of tumour microenvironmental factors on the biology of prostate tumours. My PhD work demonstrated that hypoxia could enable control therapeutic gene expression and has enabled others to purse this approach. My subsequent participation in the debate on the protective effect of hypoxia after radiation exposure, and its ability to affect the efficacy of commonly used chemotherapeutic agents shaped my transformation into an independent PI. My first grant selected for radioresistant prostate cancer cells, establishing a unique model to characterise the molecular mechanisms of the radiation response. I tested the prognostic potential of miRNAs, small, non-coding RNAs that negatively regulate gene expression, and identified novel miRNAs regulating radioresistance in prostate cancer cells. I proposed that the signalling pathways that regulate several cancer cells capabilities such as Notch and YB-1 as key to the survival of cancer cells to radiation, and identified deregulation of the Notch-3 receptor across cell line models of advancing disease stages and in patient specimens of high grade disease. My second grant examined the commercial potential of these findings for the development of a novel diagnostic test. Along the way, I have learnt that heterogeneity will prevail, and diversity in approaches is essential. I pushed the boundaries, investigating physical properties (functional imaging), learning the practical challenges of delivering radiotherapy, enabling my colleagues at the Discipline of Radiation Therapy to progress their research in the process. Together, we have demonstrated that molecular imaging techniques, such as magnetic resonance imaging (MRI), can advance our ability to assess prostate cancer; we have explored the impact of patient rotation on the treatment of lung cancer patient with radiotherapy. More recently I have questioned the potential impact of the differences between male and female biology. My next research objective is to enable my discoveries to inform both the prediction of clinical outcome to a radiotherapy treatment and the optimisation of a radiotherapy protocol to best treat tumours. To do so, next propose to devise a novel strategy for the selective generation of a large amount of DNA damage in single cancer cells. I have already, amongst others, demonstrated increased cell survival capacity in response to radiation exposure is associated with both reduced induction of DNA DSB and increased DNA repair capacity. While efforts to modify the DNA damage response are yielding encouraging results, this work will leverage my expertise and network, generate new opportunities while maintain the reputation of my unique, internationally recognised radiobiology lab and extended research group.

• Title

  Tumours have a sex: impact on the response of bladder cancer to therapy.
  Summary

  Years of experience with ionising radiation and/or chemical poisons has taught us that damaging the genome - cutting the DNA molecule that it consists of - can block the development of cancer and delay death. This project will investigate sex as a biological variable affecting the ability of bladder cancer to overcome these cuts and escape destruction. This work will compare the presence of the tools required to repair this damage in female and male bladder cancer patients, experimentally manipulate their availability and test their relationship with the cancer development process in laboratory models.
  Funding Agency

  PhD Provost Award 2021
  Date From

  October 2021
  Date To

  October 2025
• Title

  Reduced oxygenation does not protect all prostate cancer cells from radiation: a new role for hypoxia in radiation therapy?
  Summary

  Oxygen is essential for optimal cytotoxicity of radiation therapy. In the absence of oxygen at the time of radiation exposure, cell survival is commonly expected to increase by up to three-fold. We proposed that the proportion of cells completely deprived of oxygen within tumours may not be sufficiently large to be clinically significant and hypothesised that the surrounding hypoxic cells in fact may govern tumour response to radiotherapy. To test this hypothesis, this study proposed to re-examine the radioresponse of hypoxic prostate cancer cells and determine the consequences of these potentially clinically relevant oxygen levels.
• Title

  Tumours have a sex: Impact on disease development and treatment response.
  Summary

  The issue of sex bias or sex dismorphism in science is rapidly gaining momentum. Sex is a variable that affects several biological functions including both the innate and adaptive immune systems, the mode of stress-induced cell death and pain responses. Sex-specific studies have highlighted that drugs may affect males and females differently. But the impact of sex on the radiation response remains largely unstudied. Our lab investigates the impact of sex as a biological variable in the response to anti-cancer treatment. This work would involve the generation of in vitro survival curves using both female and male cancer cell lines, the review of published and recorded clinical data, and a solid evaluation of the potential sex-specific differences in the behaviour of cancer cells.
  Date From

  October 2019
  Date To

  Ongoing
• Title

  Creating the next-generation Cancer cell DNA damaging agent
  Summary

  Our insufficient, biologically challenged or poorly targeted ability to generate fatal DNA damage in cancer cells is recognised as an underlying major limiting factor to therapeutic efficacy of current cancer treatments. While efforts to modify the DNA damage response are yielding encouraging results, few novel anti-cancer DNA damaging agents are emerging. This project aims to create the next generation cancer cell DNA damaging agent.
  Date From

  October 2020
  Date To

  Present
• Title

  Development of a Companion diAgnostic teSt for radiotheraPy prostAte canceR patients (CASPAR)
  Summary

  There is an unmet need to develop companion diagnostic tests that can guide patients and their clinicians through the treatment decision process. This project propose assesses a novel protein for its prognostic and therapeutic potential in high risk radiotherapy prostate cancer patients. The long-term focus of CASPAR is to develop a novel companion diagnostic test and therapeutic combination that can allow personalized prescription of radiotherapy for these patients.
  Funding Agency

  Science Foundation Ireland
  Date From

  01/01/2017
  Date To

  31/128/2017
• Title

  Prognosis potential of miRNAs in high risk radiotherapy prostate cancer patients
  Summary

  Failure to identify tumours with a radioresistant phenotype in the 1,000+ Irish prostate cancer patients/year receiving radiation therapy (RT) is associated with recurrence and decreased overall survival in approximatively 300-400 of these men, particularly those with localised Gleason 8-10 prostate carcinoma. This study aims to identify a miRNA panel that can be detected in diagnostic tissue biopsy specimen from high-risk patients, which will assist the identification of the 30-50% who are at greater risk of biochemical failure following RT.
  Funding Agency

  Irish Cancer Society
  Date From

  01 December 2012
  Date To

  01 December 2016

Oncology and cancer biology, Oncology and cancer biology,

• Travel Award, Radiation Research Society, USA 2010
• Faculty of Health Sciences, Dean's Teaching Award 2015
• Early investigator award, Association for Radiation Research (UK) 2007
• GANIL (Grand Accélérateur d'Ions Lourds) Beam Access Award 2018
• Faculty of Health Sciences, Dean's Research Award 2020
• Early Career Investigator Award, Radiation Research Society (USA) October 2017
• Irish Cancer Society, Prostate Cancer Project Grant 01/12/2012
• 6th St Lukes Young Investigator Award 2009
• Science Foundation Ireland, TIDA 2017
• Cancer Immunology Stimulus Award 2018
• Election to Fellowship, Trinity College Dublin 10/04/2017

• Radiation Research Society (USA) Present
• European Society for Radiotherapy and Oncology (ESTRO) Present
• Irish Association for Cancer Research Present
• Irish Radiation Research Society Present

• Royal College of Surgeons in Ireland, Faculty of Radiologists, FRCR Radiobiology Examination Preparation course (Radiation Oncology Registrars) (Radiobiology Course development, Instructor (Radiobiology); Tutor (Statistics)) June
• Irish Radiation Research Society (Deputy Chair) December
• GANIL (Grand Acclrateur d'Ions Lourds) - Application Reviewing Committee member June
• Invited member, The Advisory Committee for Radiation Oncology Practice (ACROP) committee. March
• International Exchange, Global Health Disparities Research Training Program, Division of Public Health, Icahn School of Medicine at Mount Sinai, New York, USA. (Invited Mentor) July
• Cancers (Special Issue Invited Guest Editor) July
• St Luke's Radiation Oncology Network - Radiobiology Steering Committee (Invited member) May
• Editor, Clinical and Translational Radiation Oncology (Elsevier) September
• Grant Reviewer - Medical Research Council (UK), COST Action (European Commission), EIT Health COVID Rapid response (European Commission), ERA PerMed (European Commission) June
• The Wellcome - HRB Irish Clinical Academic Training Programme (Supervisor) June
• University of New South Wales, Australia (PhD external examiner) November
• Irish Radiation Research Society (Secretary) December
• Queen's University Belfast, Northern Ireland (PhD external examiner) December
• Member, History Committee, Radiation Research Society (USA). January
• European Society for Radiotherapy and Oncology, ESTRO 2021 Conference Scientific Advisory Group (Radiobiology Symposium development, Session chair, Abstract Reviewer) April
• Irish Radiation Research Society (Treasurer) December
• St Luke's Radiation Oncology Network - Radiobiology Steering Committee (Invited member) May
• European Society for Radiotherapy and Oncology, ESTRO 2020 Conference Scientific Advisory Group (Radiobiology Symposium development, Session chair, Abstract Reviewer) December
• Nature Scientific Reports (Editor) June
• Queen's University Belfast, Northern Ireland (PhD external examiner) December
• Irish Radiation Research Society (Deputy Chair) December
• University of New South Wales, Australia (PhD external examiner) November
• Journal Reviewer - Molecular Biology Reports Urology Advances in Radiation Oncology Experimental and Therapeutic Medicine Physics and Imaging in Radiation Oncology technical innovations and patient support in radiation oncology International Journal of Molecular Medicine Cancers June
• European Society for Radiotherapy and Oncology, ESTRO 2021 Conference Scientific Advisory Group (Radiobiology Symposium development, Session chair, Abstract Reviewer) April
• The Wellcome - HRB Irish Clinical Academic Training Programme (Supervisor) June
• Irish Radiation Research Society (Treasurer) December
• University of Cape Town, South Africa (PhD external examiner) September
• University of Manchester, UK (PhD external Examiner) July
• Prostate Cancer Research UK. Invited member, Research Advisory committee. July
• Irish Radiation Research Society (Chair) February
• International Exchange, Global Health Disparities Research Training Program, Division of Public Health, Icahn School of Medicine at Mount Sinai, New York, USA. (Invited Mentor) July
• European Society for Radiotherapy and Oncology, Radiobiology Committee (Invited Member)
• Grant Reviewer - Medical Research Council (UK), COST Action (European Commission), EIT Health COVID Rapid response (European Commission), ERA PerMed (European Commission) June
• Grant Reviewer - Leading Fellows Postdoc Programme (The Netherlands) March
• Journal Reviewer - Molecular Biology Reports Urology Advances in Radiation Oncology Experimental and Therapeutic Medicine Physics and Imaging in Radiation Oncology technical innovations and patient support in radiation oncology International Journal of Molecular Medicine Cancers June
• Specialist Examiner (Radiobiology), Royal College of Radiologists FRCR examinations, UK December
• Prostate Cancer Research UK. Invited member, Research Advisory committee. July
• Irish Radiation Research Society (Secretary) December
• Nature Scientific Reports (Editor) June
• European Society for Radiotherapy and Oncology, Radiobiology Committee (Invited Member)
• University of Manchester, UK (PhD external Examiner) July
• Clinical and Translational Radiation Oncology, Editorial Board Member. July
• Irish Radiation Research Society (Chair) February
• University of Cape Town, South Africa (PhD external examiner) September
• Protocol for treatment interruption Compensation, Lung Radiation Therapy due to COVID-19 (Radiobiology Advisor) May
• Environmental Protection Agency (EPA) Advisory Committee (Ireland) ( Minister Appointed Radiobiology advisor) July
• Basic Radiobiology Teaching Course, European Society for Radiotherapy and Oncology (Faculty member) September
• University College Dublin, School of Medicine. Professional Certificate in Radiation Safety. (Curriculum developer, Instructor). June
• European Society for Radiotherapy and Oncology, ESTRO 2020 Conference Scientific Advisory Group (Radiobiology Symposium development, Session chair, Abstract Reviewer) December
• Basic Radiobiology Teaching Course, European Society for Radiotherapy and Oncology (Faculty member) September
• Clinical and Translational Radiation Oncology, Editorial Board Member. July
• Member, History Committee, Radiation Research Society (USA). January
• Journal reviewer - Frontiers Oncology Clinical breast cancer Journal of Clinical Medicine Cells Molecular Oncology Oncology reports Oncology letters Oncotarget June
• Specialist Examiner (Radiobiology), Royal College of Radiologists FRCR examinations, UK December
• Protocol for treatment interruption Compensation, Lung Radiation Therapy due to COVID-19 (Radiobiology Advisor) May
• Royal College of Surgeons in Ireland, Faculty of Radiologists, FRCR Radiobiology Examination Preparation course (Radiation Oncology Registrars) (Radiobiology Course development, Instructor (Radiobiology); Tutor (Statistics)) June
• Environmental Protection Agency (EPA) Advisory Committee (Ireland) ( Minister Appointed Radiobiology advisor) July
• Journal reviewer - Frontiers Oncology Clinical breast cancer Journal of Clinical Medicine Cells Molecular Oncology Oncology reports Oncology letters Oncotarget June
• University College Dublin, School of Medicine. Professional Certificate in Radiation Safety. (Curriculum developer, Instructor). June
• Cancers (Special Issue Invited Guest Editor) July
• GANIL (Grand Accélérateur d'Ions Lourds) - Application Reviewing Committee member June
• Invited member, The Advisory Committee for Radiation Oncology Practice (ACROP) committee. March
• Grant Reviewer - Leading Fellows Postdoc Programme (The Netherlands) March
• Editor, Clinical and Translational Radiation Oncology (Elsevier) September